10 Results for "

Ravtansine

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "Ravtansine" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-12454
CAS No.: 796073-69-3
Purity:  99.64%
Synonyms: Ravtansine
Research Areas:  

Cancer

DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99542
CAS No.: 2254086-60-5
Synonyms: SAR-408701; HuMAb2-3-SPDB-DM4
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-141607
CAS No.: 1238517-16-2
Purity:  99.09%
Synonyms: BT-062; nBT062-DM4
Research Areas:  

Cancer

Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99493
CAS No.: 868747-45-9
Synonyms: IMGN242; huC242-DM4
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
loading...
    loading...
Cat. No.: HY-P99054
CAS No.: 2349294-95-5
Synonyms: SAR-408377; PF-08046050 Antibody; SAR445953 Antibody

Research Areas:  

Cancer

Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542) .
loading...
    loading...
Cat. No.: HY-P99352
CAS No.: 1954758-84-9
Synonyms: Anti-MSLN Antibody

Research Areas:  

Cancer

Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-141606
CAS No.: 1375258-01-7
Purity:  99.36%
Synonyms: BAY 94-9343
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
loading...
    loading...
Cat. No.: HY-P99967
CAS No.: 1204740-23-7

Target:  

ADC Antibodies

Research Areas:  

Cancer

Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
loading...
    loading...
Cat. No.: HY-P99788
CAS No.: 2145109-70-0
Synonyms: CX-191; CX-2009 Antibody

Research Areas:  

Cancer

Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
loading...
    loading...
Cat. No.: HY-P99789
CAS No.: 2145115-85-9
Synonyms: CX-2009; CD166
Research Areas:  

Cancer

Praluzatamab ravtansine (CX-2009) is an anti-CD166 antibody drug conjugate (ADC) with an Kd value of 25.15 nM. Praluzatamab ravtansine contains an anti-CD166 monoclonal antibody Praluzatamab (HY-P99788) conjugated to the microtubule inhibitor DM4 (HY-12454). Praluzatamab ravtansine shows tumor targeting and can be used for the study of lung cancer and breast cancer .
loading...
    loading...